Pharmacodynamic (PD) assessment of blood pressure (BP) in a randomized dose-ranging trial of sorafenib (S).

3016 Background: Hypertension may be a PD marker for efficacy of VEGF signaling pathway (VSP) inhibitors. The effects of S doses >800 mg/d on BP are not well characterized. To determine precisely t...